secwatch.observer — SEC 8-K summary
======================================

Issuer:     Amylyx Pharmaceuticals, Inc. (AMLX)
CIK:        0001658551
Form:       8-K
Filed at:   2024-02-22T23:59:59+00:00
Accession:  0000950170-24-018409
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Amylyx reports FY 2023 net income $49.3M vs loss; product revenue $380.8M
-------------------------------------------------------------------------

- Full-year 2023 net product revenue $380.8M; Q4 revenue $108.4M vs $102.7M in Q3 2023.
- Net income of $49.3M (diluted EPS $0.70) for 2023 vs net loss of $198.4M ($3.39 loss per share) in 2022.
- Cash, cash equivalents and short-term investments of $371.4M at Dec 31, 2023 vs $355.0M at Sep 30, 2023.
- Phase 3 PHOENIX trial topline data expected Q1/Q2 2024; Phase 3 ORION trial dosed first patient Dec 2023, data 2025-2026.
- Appointed Camille Bedrosian CMO, Linda Arsenault CHRO, Dan Monahan GM & Head of U.S. Commercial in late 2023/early 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1658551/000095017024018409/0000950170-24-018409-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1658551/000095017024018409/amlx-20240222.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-018409

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer